<DOC>
	<DOCNO>NCT01283555</DOCNO>
	<brief_summary>The primary objective study compare effect two vaginal applicator , deliver candidate microbicide Tenofovir , symptoms sign irritation external genitalia , cervix vagina see colposcopy seven day twice daily use . The secondary objective : 1 . Evaluate compare dose accuracy precision user-filled applicator pre-filled applicator candidate microbicide , Tenofovir . 2 . Compare acceptability user-filled applicator pre-filled applicator .</brief_summary>
	<brief_title>Comparative Safety Study Two Vaginal Applicators With Tenofovir</brief_title>
	<detailed_description />
	<mesh_term>Anti-Infective Agents</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Female Age 18 50 , inclusive Premenopausal In good health report individual Have regular menstrual cycle ( 24 35 day ) Low risk sexually transmit infection ( one sexual partner last three month ) Not pregnant risk pregnancy ( must either tubal ligation , currently use hormonal method contraception ) Negative urine pregnancy test Willing abstain sexual intercourse masturbation two 7day period applicator use Willing abstain use vaginal product course study ( include douching , use vaginal applicator medication , lubrication , sex toy , ) Willing follow procedural requirement study Willing able provide inform consent study participation Willing provide investigator phone number address reach study History hysterectomy Pregnancy within two month last pregnancy outcome ( delivery , spontaneous induced abortion , medical surgical management ectopic pregnancy ) Postmenopausal Breastfeeding Use intrauterine device ( IUD ) , cervical cap diaphragm contraceptive purpose Diagnosis treatment sexually transmit disease within past 30 day ; More one sexual partner last 3 month Has surgery external genitalia , vagina , cervix within past 3 month ; Current past use antiretroviral therapy include limited systemic Tenofovir ( VireadÂ® ) Current anticipate use drug daily basis may reduce renal function ( e.g . acyclovir ibuprofen ) liver function ( e.g . Tylenol ) HIV positive time screen Hepatitis B surface antigen ( HBsAg ) positive time screen Positive test result Neisseria gonorrhea , Chlamydia trachomatis , Trichomonas vaginalis time screen . At baseline colposcopic exam ( Visit 2 ) , finding involve disruption epithelium disruption blood vessel deep disruption epithelium alone . Any area epithelium bleeding consider deeply disrupt . Any abnormal finding colposcopic exams opinion investigator , preclude participation study At baseline exam , clinical symptom sign vaginitis vulvitis confirm wet mount exam discharge . Note : If vaginitis vulvitis present either baseline exam ( visit 2 10 ) , volunteer treat reschedule new baseline exam one week application last treatment dose . If sign symptom still present reschedule baseline exam Visit 2 , volunteer enrol study . If sign symptom still present reschedule baseline exam Visit 10 , volunteer discontinue study . Serum chemistry ( glucose , creatinine , bilirubin , AST [ aspartate aminotransferase ] ALT [ alanine transaminase ] ) within normal expect level accord specification local laboratory . Hemoglobin , hematocrit total white blood cell within 15 % low upper limit normal level accord specification local laboratory . Participation research study 30 day prior screen and/or plan participate research study entire study duration .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Microbicide , Applicator , Safety</keyword>
</DOC>